TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Metformin Treatment in Infants After Perinatal Brain Injury

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~HIE Patients:~1. \> 35 weeks gestation at time of birth~2. ≤3 months at time of consent~3. Clinical diagnosis of HIE~4. Infant received therapeutic hypothermia for the treatment of HIE~5. Family lives within one hour distance of the Hospital for Sick Children (in order to facilitate home visits)~Preterm Infants:~1. \<32 weeks gestation at time of birth~2. 36-44 weeks corrected (postmenstrual) gestational age at time of metformin administration~3. Clinical team anticipates hospitalization at SickKids for at least 1 week after study enrollment~Exclusion Criteria:~1. Have a known genetic or chromosomal disorder.~2. Congenital or acquired liver or kidney disease that might, in the opinion of the Principal Investigator or delegate, affect drug metabolism.~3. History of hypoglycemia in the newborn period requiring glucose infusion rate \> 10 mg/kg/min or treatment with glucagon or diazoxide.~4. Any condition or diagnosis, that could in the opinion of the Principal Investigator or delegate, interfere with the participant's ability to comply with study instructions, might confound the interpretation of the study results, or put the participant at risk~5. \>3 months of age at the time of enrollment (term HIE patients only)~6. Weight \<10%ile based on WHO growth charts at time of initiation of study drug (term HIE patients only).~7. Maternal use of metformin while actively breastfeeding.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Months
- Healthy Volunteers: f

Study Arms:
- HIE: 20 mg/kg (Type: EXPERIMENTAL): None
- HIE: 25 mg/kg (Type: EXPERIMENTAL): None
- Preterm: 15 mg/kg (Type: EXPERIMENTAL): None
- Preterm: 20 mg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Registration and Treatment of Pain During Eye Examination of Prematurity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants \< 32 weeks of gestational age (\< 31+6 weeks)~Exclusion Criteria:~* Infants with ongoing analgesic treatment

- Gender: ALL
- Minimum Age: 31 Weeks
- Maximum Age: 37 Weeks
- Healthy Volunteers: f

Study Arms:
- paracetamol (Type: EXPERIMENTAL): Paracetamol mixture 20 mg/kg + pacifier and sucrose
- placebo (Type: PLACEBO_COMPARATOR): pacifier and sucrose only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~2. Presence of an active hematological malignancy.~3. Presence of measurable disease.~4. Hematological malignancy has been previously treated, has relapsed after or progressed during prior therapy, and has limited potential for benefit from currently available therapy including hematopoietic stem cell transplantation.~5. At least 2 weeks post any treatments/therapies at the time of first dose.~6. Adequate bone marrow function.~7. Adequate hepatic function.~8. Adequate renal function.~9. Normal coagulation panel.~10. Negative antiviral serology.~11. Willingness to use effective contraception.~Exclusion Criteria:~1. Central nervous system malignancy~2. Gastrointestinal disease~3. Significant cardiovascular disease~4. Significant ECG abnormalities.~5. Ongoing risk for bleeding due to active peptic ulcer disease, bleeding diathesis or requirement for systemic anticoagulation~6. Ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections)~7. Pregnancy or breastfeeding.~8. Major surgery within 4 weeks before the start of study therapy.~9. Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids~10. Use of drugs that could prolong the QT interval within 7 days before the start of study therapy.~11. Use of drugs that might pose a risk of a drug-drug interaction within 2-7 days before the start of study therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tomivosertib (eFT-508) Escalation Cohort (Type: EXPERIMENTAL): This portion of the study will evaluate the safety and pharmacology of a range of Tomivosertib (eFT-508) doses administered daily in subjects with previously treated lymphomas
- Tomivosertib (eFT-508) Expansion Cohort (Type: EXPERIMENTAL): This portion of the study provides cohort expansion to further explore the safety, pharmacology, and clinical activity of a single dose level of Tomivosertib (eFT-508) monotherapy in subjects with specific previously treated lymphomas

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Advanced Echocardiographic Evaluation of Nebivolol

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of hypertension~2. Written informed consent before initiation of any study related procedure~3. Baseline Blood pressure \> 140 systolic or \>90 diastolic if on no antihypertensive therapy.~4. Currently taking one antihypertensive or one antihypertensive and one diuretic for the treatment of hypertension.~Exclusion Criteria:~1. Physical limitations resulting in a limited ability to walk on treadmill for stress echo~2. Intolerance to beta blockers~3. On more than one medication for the treatment of hypertension unless the second medication is a diuretic.~4. Currently pregnant or breast feeding.~5. LFT \> 3 X ULN~6. HgA1C \> 7~7. Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within past 30 days of enrollment~8. Unwilling to follow protocol or return for study related procedures.~9. Any of the following conditions:~   Coronary artery disease Heart failure Valvular heart disease Ischemic heart disease Atrial fibrillation Pacemaker ICD Hyperlipidemia Diabetes Mellitus Stroke/TIA Anemia COPD Asthma Renal failure requiring dialysis Liver failure Cirrhosis Thyroid dysfunction~10. Any other medical condition that in the PI's opinion could affect myocardial function.~11. Current ETOH or illicit drug abuse -

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Nebivolol 5 or 10 mg, oral, daily (Type: EXPERIMENTAL): Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Targeted Intraoperative Therapy Registry at Bethesda North Hospital (TARGIT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female~* Age 45 or greater~* Diagnosed with operable invasive breast cancer, T1 and T2 (\< 3.5 cm), N0, M0, confirmed by cytological or histological examination~* Suited for breast conserving surgery~* Have had an ipsilateral (same side as current cancer) diagnostic mammogram within 12 months of enrollment~Exclusion Criteria:~* age 44 or less~* Axillary lymph node positive breast cancer~* Invasive lobular cancer~* Tumor size \> 3.5 cm~* Extensive Intraductal Component (EIC= \> 25% of the lumpectomy specimen involved with ductal carcinoma in situ, DCIS) as assessed on surgical pathologic lumpectomy specimen~* Multicentric cancer in the same breast not amenable to excision with a single lumpectomy~* Inability to assess pathologic margin status~* Synchronous bilateral breast cancer at the time of diagnosis.~* Ipsilateral breast had a previous cancer and/or prior in-field radiation.~* Patients known to have BRCA1/2 gene mutations~* Neoadjuvant treatment (hormones or chemotherapy)

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Virtual Reality on Perception of Pain and Anxiety by Hysteroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with an established indication for diagnostic hysteroscopy according to the Spanish Society of Gynecology and Obstetrics (SEGO) criteria collected in its document of consensus, updated in 2013, with the title of Hysteroscopy in consultation.~* Age between 18 and 75 years.~* Suitable cultural level for the understanding of the characteristics of the study.~* Signature of informed consent.~Exclusion Criteria:~* Not be within the criteria established by SEGO for the realization of a hysteroscopy diagnostic.~* Existence of contraindication for hysteroscopy.~* Present some type of disease or disability that can intervene in the object of the study: visual deficit, auditory or sensory severe, illnesses or mental syndromes.~* Having suffered seizures, loss of knowledge, or other symptoms related to epileptic disorders that discourages the use of virtual reality glasses.~* Women who cannot tolerate the pain at the beginning and during hysteroscopy.~* Not signature of informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Hysteroscopy & Virtual reality glasses (Type: EXPERIMENTAL): Hysteroscopy with use of virtual reality glasses
- Hysteroscopy (Type: ACTIVE_COMPARATOR): Hysteroscopy without use of virtual reality glasses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed squamous cell anal carcinoma~  * Keratinizing or non-keratinizing~ * The following stages are eligible:~    * T2, N0, M0 with maximum tumor diameter at least 4 cm~   * T3-T4, N0, M0~   * Any T, N1-N3, M0~* Tumor located in the anal canal OR in the anal margin and infiltrating the anal canal~* No primary adenocarcinoma of the anus~* Measurable disease~PATIENT CHARACTERISTICS:~Age~* 18 to 75~Performance status~* WHO 0-1~Life expectancy~* Not specified~Hematopoietic~* Granulocyte count greater than 2,000/mm\^3~* Platelet count greater than 100,000/mm\^3~Hepatic~* Not specified~Renal~* Creatinine less than 1.4 mg/dL~Cardiovascular~* No grade I angina pectoris with clinical symptoms within the past 3 months~* No grade II-IV angina pectoris within the past 3 months~* No stage II or greater distal arteritis~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No other prior malignancy except adequately treated basal cell skin cancer or carcinoma in situ of the cervix~* No psychological, familial, sociological, or geographical condition that would preclude study compliance and follow-up~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No other concurrent chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No other concurrent radiotherapy~Surgery~* No prior colostomy~Other~* No prior treatment for anal cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasability of a Care Pathway Integrating Collaborative Tele-expertise to Prevent Recurring Hospitalisations for Diabetic Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetic patients hospitalized on an unscheduled basis in the diabetology department of one of the 8 study centers.~* Patients with at least two unscheduled hospitalizations in less than one year (i.e. at least one other hospitalization in the last 365 days in addition to the hospitalization on the day of the pre-inclusion visit).~* Patient with diabetes for more than one year at the time of inclusion~* Patients affiliated to or beneficiary of a health insurance plan.~Exclusion Criteria:~* Patients with significant language barrier~* Homeless patients.~* Patients in a period of exclusion determined by another study.~* Minor patients.~* Patients under legal protection, guardianship or curatorship.~* Patient for whom it is impossible to give informed information.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All patients on the basic diabetic program, eligible for an individualized care pathway. (Type: EXPERIMENTAL): This research aims to demonstrate the feasibility of telemedicine through collaborative tele-expertise for the collegial definition of an individualized care pathway, in the context of diabetic patients with unscheduled hospitalizations repeated throughout the year (≥ 2/year). The feasibility will be assessed by the number of patients who have had at least 3 of the 4 planned follow-up visits, that is to say, who are eligible for the individualized care pathway.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Infusion of Local Anesthetic for Optimal Post Operative Pain Control Following Hemorrhoidectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for hemorrhoidectomies at NMCP~Exclusion Criteria:~* Any patient with co-existing active purulent infection (i.e. abscess).~* Any patient who has had previous surgical intervention for his/her hemorrhoidal disease. Previous simple incision to treat a thrombosed hemorrhoid is not considered a surgical intervention for the purposes of this study. The minimal scar produced by a small incision would not alter post-operative pain following removal of a hemorrhoidal column.~* Any patient allergic to local anesthetics or oral pain medications~* Any patient with a history of chronic pain~* Any patient allergic to or has had an adverse reaction (i.e. history of gastrointestinal bleed) to a non-steroidal anti-inflammatory drugs (NSAIDs)~* Any patient pregnant patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Pump device (Type: PLACEBO_COMPARATOR): One arm will have continuous subcutaneous infusion of normal saline.
- Bupivacaine (Type: ACTIVE_COMPARATOR): will receive continuous infusion of bupivacaine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: REVIparin-BRIDging-in a General Practice Setting in GErmany

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients \> 18 years old~* Requiring prophylaxis/bridging treatment with reviparin, e.g. for the prevention of venous thromboembolism in general and orthopaedic surgery, due to the decision of the treating physician~Exclusion Criteria:~* Hypersensitivity to reviparin or one of the excipients of Clivarin® or other low-molecular-weight heparin preparations and/or heparin, e.g. confirmed or suspected immune-mediated heparin-induced thrombocytopenia (type 2)~* Severe renal impairment (creatinine clearance \< 30 ml/min)~* Bleeding: like other anticoagulants, reviparin should not be used in conditions associated with an increased risk of bleeding, e.g. acute bleeding, haemorrhagic diathesis, coagulation factor deficiencies, severe thrombocytopenia, untreated arterial hypertension, bacterial endocarditis and subacute endocarditis, acute-onset gastrointestinal ulcers or haemorrhages, brain haemorrhage, spinal or ear or eye surgery, intraocular bleeding or corresponding injuries within the past 6 months~* Severe hepatic or pancreatic impairment~* Children~* Patients with a body weight \< 45kg~* Life expectancy of less than 3 months~* Pregnant women (due to the generally very long duration of treatment with LMWH in female patients who are already on anticoagulation therapy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prolotherapy Versus Steroids for Thumb Carpo-metacarpal Joint Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>45~* Ability to make follow-up visits over the 6 month protocol~* Ability to give informed consent~* Eaton grade 2-3 thumb carpo-metacarpal joint osteoarthritis with pain over 3/10 on visual analogue scale with symptoms present greater then 6 months.~Exclusion Criteria:~* Recent trauma to the hand or wrist or fractures eeen on radiographs~* Eaton grade 1, or 4 joints affected~* Metabolic bone disease~* Recent systemic or localized infection (within last 2 weeks)~* History of rheumatologic disease~* Allergies to injected solutions~* Thumb carpo-metacarpal joint injections in the prior 6 months.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Prolotherapy group (Type: EXPERIMENTAL): Subjects randomized to this arm will receive injection(s) of 10% dextrose solution in the affected thumb joint.
- Corticosteroid Group (Type: ACTIVE_COMPARATOR): Subjects randomized to this arm will receive injection(s) of betamethasone solution in the affected thumb joint.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Narrow-band (NB)-UVB vs. Bath-PUVA and NB-UVB Plus Salt Water Baths in Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with moderate to severe disease AD with SASSAD-Score \> 25~* Age \> 18 years~* No topical steroids or topical/systemic antibiotics within the last 2 weeks, no systemic glucocorticosteroids or other immunosuppressive agents within the last 8 weeks, no phototherapy within the last 12 weeks before inclusion~Exclusion Criteria:~* Pregnancy or lactation~* Skin cancer or dysplastic naevi, photosensitive skin diseases, autoimmune diseases or relevant cardiovascular diseases~* Photo-skin type I according to Fitzpatrick~* severe cardiovascular disease~* intense UV radiation (tanning beds, sun exposure, phototherapy, etc.) 8 weeks before the start of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NB-UVB (Type: ACTIVE_COMPARATOR): NB-UVB irradiations adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session.
- Bath-PUVA (Type: ACTIVE_COMPARATOR): Phototherapy with UVA irradiation following bathing in psoralen water
- NB-UVB plus salt water baths (Type: ACTIVE_COMPARATOR): Balneophototherapy with NB-UVB and 3% Dead Sea salt water baths

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes~* Non diabetic~Exclusion Criteria:~* Currently taking medication such as thiazolidinediones, metformin, Exenatide, or sitagliptin~* Chronic condition such as chronic heart failure CHF), Coronary Artery Disease (CAD), or chronic renal failure (CRF)~* Anemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Diabetic Group (Type: EXPERIMENTAL): Participants with Type 2 diabetes
- Non-diabetic Group (Type: ACTIVE_COMPARATOR): Participants who are non-diabetic will serve as control. treatment is matched to experimental group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues